ANNOUNCEMENT

Take a look at the MedCity ENGAGE program, with expert speakers from leading organizations. Reserve your place today.

Topic: Athersys

Athersys prepares for stroke, heart attack phase 2 clinical trials

Athersys prepares for stroke, heart attack phase 2 clinical trials

August 10, 2011 5:44 pm by | 0 Comments

Stem cell therapy developer Athersys (NASDAQ:ATHX) plans to begin phase 2 clinical trials of its MultiStem therapy for stroke and heart attack patients by the end of the year.Moving ahead ... Read more
Athersys more threatened than most by falling share price

Athersys more threatened than most by falling share price

August 9, 2011 11:56 am by | 0 Comments

As a small biotech with little revenue, no profits and no products on the market, stem cell therapy developer Athersys (NASDAQ:ATHX) is particularly vulnerable to big drops in its share ... Read more
Athersys reports positive results from early heart attack clinical trial

Athersys reports positive results from early heart attack clinical trial

June 14, 2011 10:14 am by | 0 Comments

Athersys (NASDAQ:ATHX) reported that results from a phase 1 trial of its stem cell therapy suggest its MultiStem technology could hold benefits for heart attack patients.The positive results from a ... Read more
Athersys reports positive results from early GvHD clinical trial

Athersys reports positive results from early GvHD clinical trial

May 25, 2011 11:12 am by | 0 Comments

Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive interim results from a phase 1 clinical trial in patients with leukemia or similar blood cancers.The trial showed that the company’s MultiStem ... Read more
Athersys plans to begin first stroke clinical study by end of year

Athersys plans to begin first stroke clinical study by end of year

May 5, 2011 6:30 pm by | 0 Comments

Stem cell therapy developer Athersys (NASDAQ:ATHX) plans to begin the first clinical study of its MultiStem technology in stroke patients by the end of the year.The planned double-blind, placebo-controlled study ... Read more
Athersys begins enrolling patients in first phase 2 clinical trial

Athersys begins enrolling patients in first phase 2 clinical trial

March 14, 2011 5:55 pm by | 0 Comments

Stem cell therapy developer Athersys (NASDAQ:ATHX) and partner Pfizer (NYSE:PFE) have begun enrolling patients in a phase 2 clinical trial for inflammatory bowel disease. ... Read more
Athersys to raise $13M in direct offering; shares tumble

Athersys to raise $13M in direct offering; shares tumble

January 28, 2011 11:15 am by | 0 Comments

Stem cell company Athersys Inc. (NASDAQ:ATHX) has reached an agreement to sell about $13 million of its shares to unidentified private investors. ... Read more
Athersys stem cells show promise in treating spinal injury, study shows

Athersys stem cells show promise in treating spinal injury, study shows

January 19, 2011 10:52 am by | 0 Comments

Stem cell company Athersys completed a study showing its technology could hold therapeutic benefits in treating spinal cord injuries. Researchers found that administering Athersys' MultiStem technology to rodents with spinal ... Read more
Athersys completes patient enrollment in portion of blood cancer study

Athersys completes patient enrollment in portion of blood cancer study

January 6, 2011 9:25 am by | 0 Comments

Athersys Inc. (NASDAQ:ATHX) has completed patient enrollment in the single-dose portion of a clinical trial that's treating blood cancer patients with the company's stem cell therapy. ... Read more
Ex-Cleveland Clinic CEO Floyd Loop leaves Athersys board

Ex-Cleveland Clinic CEO Floyd Loop leaves Athersys board

January 3, 2011 12:08 pm by | 0 Comments

Floyd Loop, the former Cleveland Clinic CEO credited with turning around the once-struggling hospital, has resigned from the board of stem cell company Athersys Inc. (NASDAQ:ATHX). ... Read more
Ex-Athersys janitor accused in $340,000 stock scam

Ex-Athersys janitor accused in $340,000 stock scam

December 20, 2010 6:19 pm by | 0 Comments

A former custodian with stem cell developer Athersys (NASDAQ:ATHX) has been accused by federal prosecutors of running a stock scam that bilked would-be investors out of $340,000 over six years. ... Read more
Angiotech Pharma sells Lifespan vascular graft business for $2.8M

Angiotech Pharma sells Lifespan vascular graft business for $2.8M

November 19, 2010 10:49 am by | 0 Comments

LeMaitre Vascular Inc. (NASDAQ:LMAT) picked up Angiotech Pharmaceuticals Inc.’s (NASDAQ:ANPI) Lifespan vascular graft business for $2.8 million and spiked a distribution deal Angiotech had with former Lifespan owner Edwards Lifesciences ... Read more
Analyst: Stroke most promising use of Athersys’ MultiStem

Analyst: Stroke most promising use of Athersys’ MultiStem

November 18, 2010 11:22 am by | 0 Comments

The most promising application of Athersys Inc.'s (NASDAQ:ATHX) stem cell technology lies in treating stroke victims, according to a Morningstar Inc. analyst. "It's really market potential that leads us to ... Read more
Athersys to begin clinical trial with Pfizer; loses $3.7M in Q3

Athersys to begin clinical trial with Pfizer; loses $3.7M in Q3

November 8, 2010 6:43 pm by | 0 Comments

Athersys Inc. (NASDAQ: ATHX) has received the regulatory thumbs-up to begin a Phase 2 clinical trial of its MultiStem stem cell treatment for inflammatory bowel disease. ... Read more
Former shareholders sue Angiotech Pharma for lying

Former shareholders sue Angiotech Pharma for lying

October 7, 2010 2:15 pm by | 0 Comments

A group representing former shareholders of Angiotech Pharmaceuticals Inc. (NSDQ:ANPI) subsidiary Quill Medical Inc. are suing both companies. QSR Holdings Inc. alleges that Angiotech concealed damaging information about the sales ... Read more